Carregant...
EGFR突变晚期非小细胞肺癌患者后线接受免疫治疗的疗效分析
BACKGROUND AND OBJECTIVE: Immune checkpoint inhibitor monotherapy is reported to have little effect in advanced non-small cell lung cancer (NSCLC) patients with driver oncogenes. However, recent studies have shown that some patients with driver genes are still benefit from combination immunotherapy...
Guardat en:
| Publicat a: | Zhongguo Fei Ai Za Zhi |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
中国肺癌杂志编辑部
2021
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8174113/ https://ncbi.nlm.nih.gov/pubmed/34034457 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3779/j.issn.1009-3419.2021.104.06 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|